[Antinflammatory therapy and cardiovascular risk: a consensus view].

Fin dalla loro scoperta, circa 40 anni fa, i farmaci antinfiammatori non steroidei (FANS) hanno rappresentato una delle classi di farmaci piu utilizzate. Grazie a loro e radicalmente migliorata la capacita di controllare flogosi e dolore sia acuti che cronici. L’efficacia di questi farmaci, specialmente quando assunti cronicamente, si e sempre scontrata con un basso profilo di sicurezza specie a carico dell’apparato gastrointestinale superiore. Si stima che circa l’1% degli utilizzatori di FANS sviluppino lesioni gastro-duodenali importanti (sanguinamento e perforazione) per le quali si deve ricorrere a cure ospedaliere. Malgrado la bassa percentuale di rischio, la vasta diffusione d’uso degli antinfiammatori rende la gastropatia da FANS una causa molto frequente di ospedalizzazione e morte negli USA (1). Allo

[1]  J. Sudbø,et al.  RETRACTED: Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study , 2005, The Lancet.

[2]  M. Stampfer,et al.  Non-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women , 2005, Hypertension.

[3]  Marta L. Capone,et al.  Clinical pharmacology of etoricoxib , 2005, Expert opinion on drug metabolism & toxicology.

[4]  M. Hudson,et al.  Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. , 2005, The Journal of rheumatology.

[5]  Carol Coupland,et al.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[6]  E. Ricciotti,et al.  Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. , 2005, Journal of the American College of Cardiology.

[7]  D. Graham,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study , 2005 .

[8]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[9]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[10]  L. Melvin,et al.  Effects of estrogen with and without progestin on urinary incontinence , 2005, Journal of Family Planning and Reproductive Health Care.

[11]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[12]  M. Reilly,et al.  Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction , 2005, Annals of Internal Medicine.

[13]  Charles A. Day,et al.  Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. , 2004, Atherosclerosis.

[14]  V. Fuster,et al.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[15]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[16]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[17]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[18]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[19]  C. Patrono,et al.  Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects , 2004, Circulation.

[20]  P. Duke,et al.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[21]  H. Krumholz,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[22]  Peter C Austin,et al.  Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. , 2003, Archives of internal medicine.

[23]  E. Ricciotti,et al.  Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells , 2003, British journal of pharmacology.

[24]  W. Willett,et al.  Frequency of analgesic use and risk of hypertension in younger women. , 2002, Archives of internal medicine.

[25]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[26]  H. Guess,et al.  Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. , 2002, Archives of internal medicine.

[27]  E. Rahme,et al.  Association between naproxen use and protection against acute myocardial infarction. , 2002, Archives of internal medicine.

[28]  J. Eikelboom,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.

[29]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[30]  C. Patrono,et al.  Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. , 2000, Epidemiology.

[31]  M. Wolfe,et al.  Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.

[32]  G. FitzGerald,et al.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.

[33]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Felson,et al.  A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. , 1993, Archives of internal medicine.

[35]  G. FitzGerald,et al.  Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  G. FitzGerald,et al.  Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing , 1985, Clinical pharmacology and therapeutics.

[37]  J. White,et al.  Ibuprofen Protects Platelet Cyclooxygenase from Irreversible Inhibition by Aspirin , 1983, Arteriosclerosis.

[38]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[39]  B. Thiers.  Non-Steroidal Anti-inflammatory Drugs and the Risk of Oral Cancer: A Nested Case-Control Study , 2006 .

[40]  W. Ray,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease☆ , 2003 .

[41]  C. Nzerue.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[42]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.